Cann Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNGGF research report →
Price Chart
About the company
Cann Group Limited, established in Port Melbourne, Australia, in 2014, specializes in the comprehensive lifecycle of medicinal cannabis. This includes genetic development, cultivation, manufacturing, clinical assessment, and the distribution of therapeutic cannabis products. The company supplies these products for use within Australia and also exports them to international markets, operating under specific licenses that permit research and the cultivation of cannabis for human medicinal and scientific purposes.
- CEO
- Jennifer Lee Pilcher
- IPO
- 2021
- Employees
- 98
- HQ
- Mildura, VIC, AU
Get TickerSpark's AI analysis on CNGGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.47M
- P/E
- 0.30
- PEG
- 0.00
- P/S
- 0.97
- P/B
- 0.07
- EV/EBITDA
- -4.55
- Div Yield
- 0.00%
- Gross Margin
- -94.13%
- Op Margin
- -131.65%
- Net Margin
- 237.11%
- ROE
- 64.70%
- ROIC
- -24.67%
Latest fiscal year · YoY change
- Revenue
- $8.55M-35.5%
- Gross Profit
- $-8,048,706-256.2%
- Op Income
- $-12,001,160
- Net Income
- $20.28M+190.7%
- EPS
- $0.02+139.5%
- OCF Growth
- +86.2%
- FCF Growth
- +82.3%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.11
- RSI (14)
- 93
- Avg Volume
- 374
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cann Group reported FY23 sales growth of 115% to $13.78 million as Mildura scaled up, and management said the business is entering a new phase focused on volume, quality, and future profitability.· August 28, 2023
- Sales doubled to $13.78 million, driven by new and repeat orders from Mildura.
- Total income rose to $21.68 million, helped by the R&D rebate accrual and the gain on sale of the Southern facility.
- Production is ramping from about 3 tonnes in FY23 toward 8 tonnes to 9 tonnes this year and a goal of 12.5 tonnes.
- Management says dried flower remains the core product mix, with about 77% of units, and expects it to stay dominant for 12 to 18 months.
- A $4.46 million rights issue was completed in August, with a shortfall placement process now underway.
Cann increased revenue from sales of products and services by 115% to $13.78 million in FY23. Total income, including other sources, grew to $21.68 million. Management said FY23 sales were achieved at around 3 tonnes of production, and they are now moving toward 8 tonnes to 9 tonnes this year and ultimately 12.5 tonnes. No EPS, gross margin, or full-year profit figure was given in the call. Looking ahead, management did not give formal numeric revenue guidance, but said the focus for FY24 is scaling production, improving quality, expanding the product range, and driving stronger margins through economies of scale, with EBITDA profitability in FY25 described as entirely likely possible and the goal.
Peter Koetsier framed FY23 as a pivot point, saying the business has “taken off” and is moving toward cruising altitude as Mildura scales. He emphasized that quality and quantity are now coming through together, with dried flower and oils leading sales and new genetics and longer-term customer agreements expected to support the next phase. His tone was upbeat and confident, but he also stressed that the company is still early in commercialization and must convert production into sustained revenue.
Deborah Ambrosini said revenue from products and services rose 115% to $13.78 million, while total income reached $21.68 million. She attributed the additional income to the FY23 R&D rebate accrual and the gain on sale of the Southern facility, land, and buildings. She also noted higher operating expenses from bringing Mildura online, plus significant S3 clinical trial R&D, higher interest expense from rate rises, and added depreciation and amortization after Mildura began amortizing in the last quarter of FY22. Her key message was that operating costs should benefit from economies of scale as production increases in FY24.
Analysts asked whether the current growth rate can continue, and management said it would be “very surprised and very disappointed” if growth did not continue, given the move from 3 tonnes toward 9 tonnes and then 12.5 tonnes. Questions on product mix centered on dried flower versus oil; management said dried flower is about 77% of units, remains the mainstay for the next 12 to 18 months, and is viewed as a higher-margin category if quality stays consistent. On the capital raise, management said the target was $11.7 million, the raise was still open until October, and it was too early to judge the outcome after $4.46 million had been raised in the rights issue. Questions on profitability were met with guidance that EBITDA profitability in FY25 is a likely possibility and the goal, while overseas expansion, automation, sustainability, and customer growth were all framed as secondary to executing in Australia first.
The bullish case is that Cann appears to have crossed from build-out into operational scaling, with Mildura now producing higher-quality product and sales already up sharply. Management believes more volume, better product range, and automation should expand margins and customer uptake, while saying the current market demand in Australia is strong enough to absorb production growth.
The main risks are that the business is still early in scaling, so profits depend on executing production ramp-up and converting output into sustained sales. Management acknowledged higher costs from staffing, cultivation, manufacturing, interest, and depreciation, while the capital raise was below the original target at $4.46 million and the company is still reliant on further funding and shortfall placement discussions. Regulatory issues, especially the slow pace of medicinal cannabis driving reform, were also flagged as a drag on market growth.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 78.7%
- Shares Outstanding
- 1.66B
- Float Shares
- 1.31B
Our CNGGF coverage
Recent articles, reports, and earnings notes.
No research on CNGGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNGGF report →Cann Group Limited (CNGGF) Shareholder/Analyst Call Transcript
seekingalpha.com · Nov 4
Cann American Corp. Provides Shareholder Update
accesswire.com · Jul 9
Cann Group Limited (CNGGF) Q2 2023 Earnings Call Transcript
seekingalpha.com · Feb 27
Bearish Wave Tumbles Marijuana Stocks
benzinga.com · Sep 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.